{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:34:15Z","timestamp":1790728455707,"version":"4.1.0"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA197292, CA111412"],"award-info":[{"award-number":["CA197292, CA111412"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA200922"],"award-info":[{"award-number":["CA200922"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5P30CA077598-18"],"award-info":[{"award-number":["5P30CA077598-18"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002494"],"award-info":[{"award-number":["UL1TR002494"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>New treatments are required to enhance current therapies for lung cancer. Mesothelin is a surface protein overexpressed in non-small cell lung cancer (NSCLC) that shows promise as an immunotherapeutic target in phase I clinical trials. However, the immunosuppressive environment in NSCLC may limit efficacy of these therapies. We applied time-of-flight mass cytometry to examine the state of circulating mononuclear cells in fourteen patients undergoing treatment for unresectable lung cancer. Six patients had earlier stage NSCLC (I-IVA) and eight had highly advanced NSCLC (IVB). The advanced NSCLC patients relapsed with greater frequency than the earlier stage patients. Before treatment, patients with very advanced NSCLC had a greater proportion of CD14<jats:sup>-<\/jats:sup> myeloid cells than patients with earlier NSCLC. These patients also had fewer circulating natural killer (NK) cells bearing an Fc receptor, CD16, which is crucial to antibody-dependent cellular cytotoxicity. We designed a high affinity tri-specific killer engager (TriKE<jats:sup>\u00ae<\/jats:sup>) to enhance NK cytotoxicity against mesothelin<jats:sup>+<\/jats:sup> targets in this environment. The TriKE consisted of CD16 and mesothelin binding elements linked together by IL-15. TriKE enhanced proliferation of lung cancer patient NK cells <jats:italic>in vitro<\/jats:italic>. Lung cancer lines are refractory to NK cell killing, but the TriKE enhanced cytotoxicity and cytokine production by patient NK cells when challenged with tumor. Importantly, TriKE triggered NK cell responses from patients at all stages of disease and treatment, suggesting TriKE can enhance current therapies. These pre-clinical studies suggest mesothelin-targeted TriKE has the potential to overcome the immunosuppressive environment of NSCLC to treat disease.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1060905","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T07:44:05Z","timestamp":1677051845000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["A tri-specific killer engager against mesothelin targets NK cells towards lung cancer"],"prefix":"10.3389","volume":"14","author":[{"given":"Philippa R.","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Vallera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Ettestad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Hallstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behiye","family":"Kodal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Todhunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bendzick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hinderlie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua T.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Pulkrabek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Pastan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kratzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Felices","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,22]]},"reference":[{"key":"B1","article-title":"U.S. cancer statistics data visualizations tool [Internet]","volume-title":"Centers Dis. Control Prev. Natl. Cancer Inst. C","year":"2016"},{"key":"B2","volume-title":"SEER Cancer Statistics Review, 1975-2017","author":"Howlader","year":""},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069008","article-title":"Association of computed tomography screening with lung cancer stage shift and survival in the united states: quasi-experimental study","volume":"376","author":"Potter","year":"2022","journal-title":"BMJ"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00520-1","article-title":"Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC","volume":"18","author":"Grant","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: Nivolumab versus docetaxel in previously treated non\u2013Small-Cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199203000-00006","article-title":"Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma","volume":"16","author":"Chang","year":"1992","journal-title":"Am J Surg Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc Natl Acad Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200311000-00003","article-title":"Application of mesothelin immunostaining in tumor diagnosis","volume":"27","author":"Ord\u00f3\u00f1ez","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200302000-00002","article-title":"Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types","volume":"27","author":"Miettinen","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0578","article-title":"New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA","volume":"11","author":"Onda","year":"2005","journal-title":"Clin Cancer Res [Internet]."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2161","article-title":"Mesothelin expression in human lung cancer","volume":"13","author":"Ho","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3429","article-title":"High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis","volume":"6","author":"Thomas","year":"2015","journal-title":"Oncotarget"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1862","article-title":"Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma","volume":"20","author":"Kachala","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin immunotherapy for cancer: Ready for prime time","volume":"34","author":"Hassan","year":"2016","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0061-z","article-title":"Natural killer cells and other innate lymphoid cells in cancer","volume":"18","author":"Chiossone","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1146\/annurev-cancerbio-030518-055653","article-title":"Natural killer cells in cancer immunotherapy","volume":"3","author":"Miller","year":"2019","journal-title":"Annu Rev Cancer Biol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"205873841983959","DOI":"10.1177\/2058738419839592","article-title":"Immunomodulatory effects of chemotherapy on blood lymphocytes and survival of patients with advanced non-small cell lung cancer","volume":"33","author":"Aldarouish","year":"2019","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1163456","article-title":"Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer","volume":"6","author":"Fend","year":"2017","journal-title":"Oncoimmunology."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13219","article-title":"Blood immune cell biomarkers in lung cancer","volume":"195","author":"Riemann","year":"2019","journal-title":"Clin Exp Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.11.038","article-title":"The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC","volume":"127","author":"Mazzaschi","year":"2019","journal-title":"Lung Cancer."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2017-0175","article-title":"Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab","volume":"10","author":"Facchinetti","year":"2018","journal-title":"Immunotherapy."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00712-2","article-title":"Natural killer cells as a potential biomarker for predicting immunotherapy efficacy in patients with non-small cell lung cancer","volume":"15","author":"Cho","year":"2020","journal-title":"Target Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24835","article-title":"Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis","volume":"9","author":"Soo","year":"2018","journal-title":"Oncotarget."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27392","article-title":"Prognostic value of immune cells in the tumor microenvironment of early-stage lung cancer: A meta-analysis","volume":"10","author":"Tuminello","year":"2019","journal-title":"Oncotarget ."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2710","article-title":"IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function","volume":"22","author":"Vallera","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0837","article-title":"Potent cytolytic activity and specific IL15 delivery in a 2nd generation trispecific killer engager","volume":"8","author":"Felices","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.2.669","article-title":"Isolation of a high-affinity stable single-chain fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity","volume":"95","author":"Chowdhury","year":"1998","journal-title":"Proc Natl Acad Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/9872","article-title":"Improving antibody affinity by mimicking somatic hypermutation in vitro","volume":"17","author":"Chowdhury","year":"1999","journal-title":"Nat Biotechnol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1021\/bi00184a014","article-title":"Stabilization of the fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions","volume":"33","author":"Reiter","year":"1994","journal-title":"Biochemistry"},{"key":"B31","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S0197-2456(98)00037-3","article-title":"Power and sample size calculations for studies involving linear regression","volume":"19","author":"Dupont","year":"1998","journal-title":"Control Clin Trials."},{"key":"B32","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat Commun Nat Publishing Group;"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-derived suppressor cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-3684-7_28","article-title":"Generation of BiKEs and TriKEs to improve NK cell-mediated targeting of tumor cells","volume":"1441","author":"Felices","year":"2016","journal-title":"Methods Mol Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2013.96","article-title":"Cell biological steps and checkpoints in accessing NK cell cytotoxicity","volume":"92","author":"Mace","year":"2014","journal-title":"Immunol Cell Biol"},{"key":"B36","first-page":"595","article-title":"Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain fv immunotoxin","volume":"1","author":"Fan","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.4AB1014-499R","article-title":"Functional analysis of NK cell subsets activated by 721.221 and K562 HLA-null cells","volume":"97","author":"Lisovsky","year":"2015","journal-title":"J Leukoc Biol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S107279","article-title":"A new prognostic score based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer","volume":"9","author":"Zhu","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000399","article-title":"Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer","volume":"10","author":"Cannon","year":"2015","journal-title":"J Thorac Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-015-4397-8","article-title":"Lymphocyte to monocyte ratio is associated with response to first-line platinum-based chemotherapy and prognosis of early-stage non-small cell lung cancer patients","volume":"37","author":"Song","year":"2016","journal-title":"Tumour Biol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-019-0169-8","article-title":"Mesothelin as a biomarker for targeted therapy","volume":"7","author":"Lv","year":"2019","journal-title":"Biomark Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol Ther"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-targeted CARs: Driving T cells to solid tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discovery"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2017.08.010","article-title":"The potential and promise of IL-15 in immuno-oncogenic therapies","volume":"190","author":"Robinson","year":"2017","journal-title":"Immunol Lett"},{"key":"B46","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018028332","article-title":"First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia","volume":"3","author":"Cooley","year":"2019","journal-title":"Blood Adv"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0945","article-title":"Phase I trial of ALT-803, a novel recombinant IL15 complex, in patients with advanced solid tumors","volume":"24","author":"Margolin","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-823757","article-title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","volume":"131","author":"Romee","year":"2018","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","article-title":"ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial","volume":"19","author":"Wrangle","year":"2018","journal-title":"Lancet Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.cell.2019.04.041","article-title":"Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity","volume":"177","author":"Gauthier","year":"2019","journal-title":"Cell."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01593\/full","article-title":"A bispecific antibody-based approach for targeting mesothelin in triple negative breast cancer","volume":"10","author":"Del Bano","year":"2019","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017012369","article-title":"161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS","volume":"2","author":"Sarhan","year":"2018","journal-title":"Blood Adv"},{"key":"B54","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.cell.2017.04.014","article-title":"Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses","volume":"169","author":"Lavin","year":"2017","journal-title":"Cell"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.3390\/cancers12092659","article-title":"NK-Cell-Mediated targeting of various solid tumors using a B7-H3 tri-specific killer engager In vitro and in vivo","volume":"12","author":"Vallera","year":"2020","journal-title":"Cancers (Basel)."},{"key":"B56","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.3390\/cancers13163994","article-title":"A HER2 tri-specific NK cell engager mediates efficient targeting of human ovarian cancer","volume":"13","author":"Vallera","year":"2021","journal-title":"Cancers (Basel)."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004725","article-title":"TEM8 tri-specific killer engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity","volume":"10","author":"Kaminski","year":"2022","journal-title":"J Immunother Cancer."},{"key":"B58","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13287-022-02769-4","article-title":"Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer","volume":"13","author":"Kennedy","year":"2022","journal-title":"Stem Cell Res Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1060905\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T07:44:13Z","timestamp":1677051853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1060905\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":58,"alternative-id":["10.3389\/fimmu.2023.1060905"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1060905","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,22]]},"article-number":"1060905"}}